A-371191
CAS No. : 406228-58-8
| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-122275 |
| M.Wt: | 693.92 |
| Formula: | C36H47N5O5S2 |
| Purity: | >98 % |
| Solubility: |
A-371191 is a selective Bcl-XL antagonist with a Ki <0.5 μM, and also acts as a mitochondria-targeting agent and chemosensitizer. A-371191 restores the sensitivity of cancer cells overexpressing Bcl-XL to Cisplatin (HY-17394) and Doxorubicin (HY-15142A). A-371191 reduces tumor volume in mice with intraperitoneal tumors. A-371191 can be used in the research of acute myeloid leukemia[1].
In Vitro:A-371191 binds selectively to Bcl-XL with a Ki value of <0.5 μM, and exhibits significantly lower affinity for other anti-apoptotic Bcl-2 family proteins[1].
A-371191 accumulates and localizes to mitochondria in NIH-H460 cells[1].
Combined treatment with A-371191 (1.8-3.2 μM) restores the sensitivity of HL-60/Bcl-XL cells to Cisplatin (HY-17394) and Doxorubicin (HY-15142A), which is consistent with the response of HL-60/neo control cells[1].
In Vivo:A-371191 (75-150 mg/kg; i.p.; twice daily for 7 consecutive days) reduces the average tumor volume and exhibits efficacy comparable to that of Doxorubicin in SCID mice bearing intraperitoneal HL-60/Bcl-XL tumors[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- A-371191
- Cat. No.:
- HY-122275
- Quantity:
Your information is safe with us.